Icahn Enterprises IEP Pharma — Intangible Assets Net Including Goodwill
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetIncludingGoodwill.
The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Questions, answered.
- What is Icahn Enterprises's pharma — intangible assets net including goodwill?
- Icahn Enterprises (IEP) reported pharma — intangible assets net including goodwill of $140M in Q1 2026.
- How has Icahn Enterprises's pharma — intangible assets net including goodwill changed year-over-year?
- Icahn Enterprises's pharma — intangible assets net including goodwill decreased by 14.1% year-over-year, from $163M to $140M.
- What is the long-term trend for Icahn Enterprises's pharma — intangible assets net including goodwill?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — intangible assets net including goodwill has grown at a -12.9% compound annual growth rate (CAGR), from $1.06B to $610M.
- What does pharma — intangible assets net including goodwill mean?
- Captures the value of non-physical assets such as patents, intellectual property, and goodwill acquired by the Pharma segment. These assets are often central to the segment's competitive advantage and long-term growth strategy. Monitoring this value helps investors understand the segment's investment in innovation and its historical acquisition activity.